FindTrial
Sign In

Quavonlimab

DRUG5 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Advanced Non-Small Cell Lung CancerAdvanced Solid TumorsMelanomaPD-1 refractory melanomaStage IV non-small cell lung cancer

Phase 1

Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)
CompletedNCT03179436
Merck Sharp & Dohme LLCAdvanced Solid Tumors
Start: 2017-07-02End: 2024-04-08Updated: 2025-04-08
Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)
CompletedNCT04305041
Merck Sharp & Dohme LLCMelanoma
Start: 2020-06-26End: 2025-08-25Updated: 2025-08-29
A Phase 1/2 Open-label, Rolling-arm, Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYMAKER-U02): Substudy 02A
CompletedCTIS2023-506312-41-00
Merck Sharp & Dohme LLCPD-1 refractory melanoma
Start: 2020-07-30End: 2025-08-22Target: 58Updated: 2025-09-01

Phase 2

A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)
CompletedNCT03516981
Merck Sharp & Dohme LLCAdvanced Non-Small Cell Lung Cancer
Start: 2018-10-01End: 2025-06-13Updated: 2025-07-01
A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)
CompletedCTIS2022-500990-16-00
Merck Sharp & Dohme LLCStage IV non-small cell lung cancer
Start: 2018-12-19End: 2025-06-13Target: 84Updated: 2025-06-06

Related Papers

Triplet combination treatments with pembrolizumab (pembro) for anti–PD-(L)1–refractory advanced melanoma: Preliminary results of the phase 1/2 KEYMAKER-U02A study.
Journal of Clinical Oncology2024-06-014 citations
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results.
2023-07-1032 citations
635 KEYNOTE-495/KeyImPaCT: updated analysis of a biomarker-directed, randomized, phase 2 trial of pembrolizumab-based combination therapy for non-small cell lung cancer
Regular and Young Investigator Award Abstracts2022-11-011 citations
Abstract CT557: Phase 1/2 study of quavonlimab (Qmab) + pembrolizumab (pembro) in patients (pts) with advanced melanoma that progressed on a PD-1/PD-L1 inhibitor
Cancer Research2022-06-154 citations
457 KEYNOTE-495/KeyImPaCT: interim analysis of a randomized, biomarker-directed, phase 2 trial of pembrolizumab-based combination therapy for non–small cell lung cancer (NSCLC)
Regular and Young Investigator Award Abstracts2021-11-018 citations
Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer.
2021-07-1810 citations
426 MK-3475-U02: Phase 1/2 study of investigational agents with or without pembrolizumab versus pembrolizumab monotherapy in melanoma
Regular and Young Investigator Award Abstracts2020-11-011 citations
Abstract CT227: KEYNOTE-495/KeyImPaCT: Phase II biomarker-directed precision oncology study of pembrolizumab-based combination therapy for non-small cell lung cancer
Cancer Research2019-07-01
Abstract CT227: KEYNOTE-495/KeyImPaCT: Phase II biomarker-directed precision oncology study of pembrolizumab-based combination therapy for non-small cell lung cancer
Clinical Trials2019-07-01
Antitumor activity and safety of MK-1308 (anti-CTLA-4) plus pembrolizumab (pembro) in patients (pts) with non-small cell lung cancer (NSCLC): Updated interim results from a phase I study.
Journal of Clinical Oncology2019-05-201 citations
Biomarker-directed precision oncology of pembrolizumab-based combination therapy for non-small cell lung cancer: Phase II KEYNOTE-495/KeyImPaCT study.
Journal of Clinical Oncology2019-05-20
Phase I study of the CTLA-4 inhibitor MK-1308 in combination with pembrolizumab in patients with advanced solid tumors
Annals of Oncology2018-10-01